Harvard Bioscience Crescita futura
Criteri Future verificati 0/6
Si prevede che Harvard Bioscience aumenterà gli utili e i ricavi rispettivamente del 78.6% e 5% all'anno, mentre si prevede che l'EPS crescerà del 80.6% all'anno.
Informazioni chiave
78.6%
Tasso di crescita degli utili
80.65%
Tasso di crescita dell'EPS
| Life Sciences crescita degli utili | 18.6% |
| Tasso di crescita dei ricavi | 5.0% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 12 Aug 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento narrativa • Aug 13
HBIO: Profitability And Cash Flow Improvements Will Support Higher Future Multiple
Analysts have raised the Harvard Bioscience price target to $7.50 from $6. This reflects their view that recent profitability and cash flow efforts could support a higher future P/E multiple.Aggiornamento narrativa • Jun 12
HBIO: Reverse Split And 2026 Execution Risks Will Pressure Overvalued Shares
Analysts have lifted their price target on Harvard Bioscience to $6.00, primarily reflecting the updated modeling of the recent 1-for-10 reverse stock split. What's in the News Harvard Bioscience issued earnings guidance for the second quarter of 2026, with expected revenue in a range of US$20.5 million to US$22.5 million.Aggiornamento narrativa • May 29
HBIO: Reverse Split And 2026 Execution Uncertainty Will Shape Balanced Outlook
Analysts have updated their models for Harvard Bioscience following the 1:10 reverse split, lifting the stated price target from $0.60 to $6 as they align their valuation work with the new share count and revised long term assumptions on growth, margins and future P/E levels. Analyst Commentary Bullish Takeaways Bullish analysts are treating the 1:10 reverse split as a housekeeping move that aligns the share price, share count and stated price target.Articolo di analisi • May 07
When Should You Buy Harvard Bioscience, Inc. (NASDAQ:HBIO)?
Harvard Bioscience, Inc. ( NASDAQ:HBIO ), is not the largest company out there, but it led the NASDAQCM gainers with a...Aggiornamento narrativa • Apr 30
HBIO: Reverse Split And 2026 Outlook Will Frame Balanced Risk Reward
Narrative Update: Harvard Bioscience Analysts have reset Harvard Bioscience's price target to $6.00 from $0.60, aligning with the recent 1:10 reverse split and updated revenue expectations for 2026. Analyst Commentary Recent commentary around Harvard Bioscience focuses on how the reverse split and updated 2026 revenue expectations feed into valuation and execution risk.Aggiornamento narrativa • Apr 12
HBIO: Reverse Split And Cost Savings Plan Will Support Future Upside Potential
Narrative Update Analysts have reset their price target on Harvard Bioscience to $6, largely reflecting the recent 1:10 reverse split and the updated revenue expectations in their models. Analyst Commentary Recent research updates on Harvard Bioscience focus on the technical impact of the 1:10 reverse split and revised revenue assumptions, rather than any major shift in the underlying story.Aggiornamento narrativa • Mar 29
HBIO: Reverse Split And Cost Savings Program Will Support Future Recovery Potential
Analysts have reset their price target for Harvard Bioscience from $0.60 to $6.00, reflecting the recent 1 for 10 reverse split and updated modeling rather than a change in the underlying view on the business. Analyst Commentary Recent research updates on Harvard Bioscience have focused on recalibrating models and targets to reflect the 1 for 10 reverse split and revised revenue expectations, rather than a wholesale change in long term conviction.Aggiornamento narrativa • Mar 15
HBIO: Reset Expectations And Manufacturing Shift Will Set Up Recovery Potential
Analysts have cut their price target on Harvard Bioscience from $2.00 to $0.60, citing a reduced 2026 revenue estimate of $89.2m versus $95.6m previously and stating that the timing of any recovery is still hard to pinpoint. Analyst Commentary Recent commentary around Harvard Bioscience is focused squarely on the reset to expectations and what it could imply for the share price and business execution over the next few years.Articolo di analisi • Dec 04
Further Upside For Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Could Introduce Price Risks After 27% Bounce
Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shares have continued their recent momentum with a 27% gain in the last month...Articolo di analisi • Oct 20
Harvard Bioscience, Inc. (NASDAQ:HBIO) Looks Inexpensive But Perhaps Not Attractive Enough
Harvard Bioscience, Inc.'s ( NASDAQ:HBIO ) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong buy...Aggiornamento narrativa • Sep 11
Demographic Shifts And NIH Funding Will Unlock Biomedical Potential
Analysts have lowered Harvard Bioscience’s price target from $3.00 to $2.00 due to increased uncertainty around research funding, drug pricing pressures, tariff risks, and a generally more cautious sector outlook. Analyst Commentary Uncertainty surrounding basic research funding potentially impacting sector performance.Articolo di analisi • Aug 14
Harvard Bioscience, Inc. (NASDAQ:HBIO) Just Reported, And Analysts Assigned A US$3.00 Price Target
NasdaqGM:HBIO 1 Year Share Price vs Fair Value Explore Harvard Bioscience's Fair Values from the Community and select...Articolo di analisi • Jul 23
Does Harvard Bioscience (NASDAQ:HBIO) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • May 29
Little Excitement Around Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Revenues As Shares Take 26% Pounding
To the annoyance of some shareholders, Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shares are down a considerable 26% in...Nuova narrativa • May 15
Expanding SoHo, BTX, And Mesh MEA Will Open New Markets
Expansion of SoHo platform and BTX systems could drive revenue growth in industrial and academic markets through broader applications and bioproduction processes.Articolo di analisi • May 02
Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?
Harvard Bioscience, Inc. ( NASDAQ:HBIO ), might not be a large cap stock, but it saw significant share price movement...Articolo di analisi • Apr 11
Lacklustre Performance Is Driving Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 49% Price Drop
To the annoyance of some shareholders, Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shares are down a considerable 49% in...Articolo di analisi • Feb 07
Harvard Bioscience, Inc. (NASDAQ:HBIO) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has dived 31% in the last...Articolo di analisi • Feb 07
Why Investors Shouldn't Be Surprised By Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 31% Share Price Plunge
Unfortunately for some shareholders, the Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has dived 31% in the last...Articolo di analisi • Nov 07
Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?
Harvard Bioscience, Inc. ( NASDAQ:HBIO ), is not the largest company out there, but it saw a significant share price...Articolo di analisi • Aug 07
Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Jul 15
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story
You may think that with a price-to-sales (or "P/S") ratio of 1.3x Harvard Bioscience, Inc. ( NASDAQ:HBIO ) is...Articolo di analisi • Dec 22
Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely
The Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has done very well over the last month, posting an excellent...Articolo di analisi • Sep 23
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Harvard Bioscience fair value estimate is US$6.55 Current...Articolo di analisi • Aug 10
Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has fared very poorly over the last month, falling by a...Articolo di analisi • Apr 26
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Harvard Bioscience fair value estimate is US$6.84 Harvard...Articolo di analisi • Apr 11
Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2027 | 95 | -2 | 2 | 5 | 2 |
| 12/31/2026 | 90 | -9 | -1 | 3 | 2 |
| 6/30/2026 | 88 | -10 | -2 | 1 | N/A |
| 3/31/2026 | 86 | -10 | 1 | 3 | N/A |
| 12/31/2025 | 87 | -57 | 5 | 7 | N/A |
| 9/30/2025 | 87 | -54 | 7 | 9 | N/A |
| 6/30/2025 | 89 | -57 | 4 | 7 | N/A |
| 3/31/2025 | 91 | -58 | 0 | 3 | N/A |
| 12/31/2024 | 94 | -12 | -2 | 1 | N/A |
| 9/30/2024 | 98 | -14 | 0 | 4 | N/A |
| 6/30/2024 | 101 | -11 | 6 | 9 | N/A |
| 3/31/2024 | 107 | -9 | 11 | 14 | N/A |
| 12/31/2023 | 112 | -3 | 12 | 14 | N/A |
| 9/30/2023 | 113 | -3 | 11 | 12 | N/A |
| 6/30/2023 | 114 | -5 | 7 | 9 | N/A |
| 3/31/2023 | 115 | -2 | 4 | 5 | N/A |
| 12/31/2022 | 113 | -10 | 0 | 1 | N/A |
| 9/30/2022 | 118 | -7 | -3 | -1 | N/A |
| 6/30/2022 | 121 | -4 | -4 | -3 | N/A |
| 3/31/2022 | 121 | -6 | -3 | -2 | N/A |
| 12/31/2021 | 119 | 0 | 0 | 1 | N/A |
| 9/30/2021 | 117 | -2 | 2 | 4 | N/A |
| 6/30/2021 | 111 | -3 | 5 | 6 | N/A |
| 3/31/2021 | 105 | -4 | 6 | 7 | N/A |
| 12/31/2020 | 102 | -8 | 8 | 9 | N/A |
| 9/30/2020 | 102 | -7 | 8 | 9 | N/A |
| 6/30/2020 | 105 | -8 | 9 | 11 | N/A |
| 3/31/2020 | 112 | -7 | N/A | 9 | N/A |
| 12/31/2019 | 116 | -5 | N/A | 8 | N/A |
| 9/30/2019 | 119 | -2 | N/A | 8 | N/A |
| 6/30/2019 | 120 | 0 | N/A | 4 | N/A |
| 3/31/2019 | 122 | -1 | N/A | 4 | N/A |
| 12/31/2018 | 121 | -4 | N/A | 3 | N/A |
| 9/30/2018 | 109 | -8 | N/A | -1 | N/A |
| 6/30/2018 | 99 | -8 | N/A | 3 | N/A |
| 3/31/2018 | 86 | -7 | N/A | 2 | N/A |
| 12/31/2017 | 77 | -2 | N/A | 1 | N/A |
| 9/30/2017 | 82 | -3 | N/A | 4 | N/A |
| 6/30/2017 | 88 | -4 | N/A | 5 | N/A |
| 3/31/2017 | 96 | -4 | N/A | 5 | N/A |
| 12/31/2016 | 105 | -4 | N/A | 5 | N/A |
| 9/30/2016 | 106 | -20 | N/A | 5 | N/A |
| 6/30/2016 | 107 | -19 | N/A | 2 | N/A |
| 3/31/2016 | 110 | -18 | N/A | 0 | N/A |
| 12/31/2015 | 109 | -19 | N/A | 1 | N/A |
| 9/30/2015 | 111 | -2 | N/A | 0 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che HBIO rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che HBIO rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che HBIO rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di HBIO ( 5% all'anno) crescerà più lentamente rispetto al mercato US ( 13.4% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di HBIO ( 5% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di HBIO è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/13 09:24 |
| Prezzo dell'azione a fine giornata | 2026/09/11 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Harvard Bioscience, Inc. è coperta da 6 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Paul Knight | KeyBanc Capital Markets Inc. |
| Timothy Chiang | Northland Capital Markets |